1. Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis
- Author
-
Ann Chen, Sung Sen Yang, Shun-Min Yang, Jeng Shin Lee, Chu Yi Yang, Shih-Hua Lin, Yi Shing Shieh, Hua Lin Wu, Kuo Feng Hua, Yu Chuan Yeh, Cheng Hsiang Kuo, Chyou Wei Wei, Guey Yueh Shi, Shuk-Man Ka, Fone Ching Hsiao, and Yi Jen Hung
- Subjects
Male ,Inflammasomes ,Thrombomodulin ,viruses ,Endocrinology, Diabetes and Metabolism ,Apoptosis ,Inflammation ,Antioxidants ,Diabetes Mellitus, Experimental ,Pathogenesis ,Diabetic nephropathy ,Mice ,chemistry.chemical_compound ,NLR Family, Pyrin Domain-Containing 3 Protein ,Internal Medicine ,Animals ,Medicine ,Diabetic Nephropathies ,Mice, Knockout ,business.industry ,NF-kappa B ,NF-κB ,Inflammasome ,Genetic Therapy ,medicine.disease ,Mice, Inbred C57BL ,Diabetes Mellitus, Type 2 ,chemistry ,Immunology ,Cancer research ,medicine.symptom ,Carrier Proteins ,business ,Protein C ,medicine.drug - Abstract
Chronic inflammatory processes have been increasingly shown to be involved in the pathogenesis of diabetes and diabetic nephropathy. Recently, we demonstrated that a lectin-like domain of thrombomodulin (THBD), which is known as THBD domain 1 (THBDD1) and which acts independently of protein C activation, neutralised an inflammatory response in a mouse model of sepsis. Here, therapeutic effects of gene therapy with adeno-associated virus (AAV)-carried THBDD1 (AAV-THBDD1) were tested in a mouse model of type 2 diabetic nephropathy.To assess the therapeutic potential of THBDD1 and the mechanisms involved, we delivered AAV-THBDD1 (10(11) genome copies) into db/db mice and tested the effects of recombinant THBDD1 on conditionally immortalised podocytes.A single dose of AAV-THBDD1 improved albuminuria, renal interstitial inflammation and glomerular sclerosis, as well as renal function in db/db mice. These effects were closely associated with: (1) inhibited activation of the nuclear factor κB (NF-κB) pathway and the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome; (2) promotion of nuclear factor (erythroid-derived 2)-like 2 (NRF2) nuclear translocation; and (3) suppression of mitochondria-derived apoptosis in the kidney of treated mice.AAV-THBDD1 gene therapy resulted in improvements in a model of diabetic nephropathy by suppressing the NF-κB-NLRP3 inflammasome-mediated inflammatory process, enhancing the NRF2 antioxidant pathway and inhibiting apoptosis in the kidney.
- Published
- 2013
- Full Text
- View/download PDF